Impact Factor
3.49
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.00
230 total citations
h5-index
19
h5 depth signal
Cited share
88.3%
53 of 60
Total citations
230
Citation footprint
Metric signal
4.08
External metric anchor
Self-citation
0.4%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
121
Italy
67
Canada
27
United Kingdom
24
France
19
Citing Fields of Research
Oncology
39
Hematology
37
Immunology
35
Dermatology
19
Neurodegenerative Disorders
19
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,050
Articles tracked across the journal lifetime
Indexed publication set
60
53 cited publications
Last 12 months
26
5.2 publications/month
Open access share
15.4%
4 OA publications in the last year
Leading citing country
United States
121 citing publications
Leading citing field
Oncology
39 citing publications
Latest tracked publication
3 October 2026
10 recent records available
Coverage & Indexing History
v8n1, May 2003-
v8n1, May 2003-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Neurodegenerative Disorders
Allergies
Auto-Inflammatory Disorders
Ophthalmology
Brain Neurological Disorders
Epithelial Barriers
Broad Categories
Drug Therapy
Neurodegenerative Disorders
Allergies
Musculoskeletal Disorders
Auto-Inflammatory Disorders
Substance Abuse
Hematology
Digestive Disorders
MeSH Descriptors
Drug Design
Drug Industry
Pharmaceutical Preparations
Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14728214.2026.2726141
Open DOI
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options
02
DOI 10.1080/14728214.2026.2739626
Open DOI
Emerging drugs for diabetic macular edema: an update
03
04
DOI 10.1080/14728214.2026.2739622
Open DOI
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra
05
DOI 10.1080/14728214.2026.2731005
Open DOI
Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics
06
DOI 10.1080/14728214.2026.2706609
Open DOI
Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs
Claudins are integral components of tight junctions with emerging roles in cancer biology. Dysregulated claudin expression during malignant transformation exposes these proteins on the tumor cell surface, creating opportunities for targe...
07
DOI 10.1080/14728214.2026.2706607
Open DOI
Drug discovery progress in targeting the renin–angiotensin–aldosterone system for heart failure
08
DOI 10.1080/14728214.2026.2683554
Open DOI
At the forefront of gene-based therapies in Dravet syndrome
Dravet syndrome (DS), a catastrophic developmental and epileptic encephalopathy primarily caused by SCN1A haploinsufficiency, remains largely refractory to current antiseizure medications. In recent years, gene-targeted therapies, includ...
09
DOI 10.1080/14728214.2026.2705211
Open DOI
Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas
Advanced gastroesophageal adenocarcinomas (GEAs) continue to represent an area in need of new drug development. Targeting human epidermal growth factor receptor-2 (HER2) in GEAs has been standard since 2010 and continues to be an area of...
10
DOI 10.1080/14728214.2026.2696872
Open DOI
σ 1 receptor agonists: the new trend or an emerging therapeutic option?
Bibliographical & Catalog Notes
Description based on: Vol. 7, no. 1 (May 2002); title from cover.
Latest issue consulted: Vol. 8, no. 1 (May 2003).
Also issued online.
v. 1, no. 1 (Jul. 1996)20031219 Notice not published Printed on acid-free paper